2025年5月17~20日，歐洲心臟病學會心力衰竭協會年會暨世界急性心力衰竭大會（ESC-HFA 2025）即將在塞爾維亞貝爾格萊德盛大召開。ESC-HFA 2025是歐洲心臟病學會-心衰協會（ESC-HFA）的年度會議，旨在透過更好地預防、診斷和治療心衰，來提高患者的生活質量和壽命。
近日，會議官網公佈了本屆大會的初步日程，在Late-Breaking Science專場將公佈62項重磅研究結果。讓我們先睹為快吧！
Hottest trials and trial updates (1)
最熱門試驗和試驗更新（1）
當地時間：5月17日10:45~12:15
FINEARTS–HF: Blinded drug withdrawal
FINEARTS-HF試驗：盲法藥物撤藥
講者: Muthiah Vaduganathan
FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrinsaturation
FAIR-HF2 DZHK05試驗：羧基麥芽糖鐵在按鐵蛋白水平分層的心衰和鐵缺乏患者中的療效
講者：Stefan Anker
FUTURE-HF: Long-term safety, accuracy, and utility of a novel implantable IVC sensor for remote HF management
FUTURE-HF試驗：用於遠端心衰管理的新型下腔靜脈（IVC）感測器的長期安全性、準確性和實用性講者: Kevin Damman
SOGALDI–PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction
SOGALDI-PEF試驗：射血分數保留的心衰（HFpEF）患者使用鈉-葡萄糖協同轉運蛋白-2抑制劑（SGLT2i）聯合或不聯合醛固酮拮抗劑的療效和安全性
講者: Joao Pedro Ferreira
PRAISE-HFrEF: Glucagon-like peptide-1 receptor agonism in heart failure with reduced ejection fraction and obesity
PRAISE-HFrEF試驗：合併肥胖的射血分數降低的心衰（HFrEF）患者，進行胰高血糖素樣肽-1受體激動劑（GLP-1RA）治療的療效
講者: Varun Sundaram
HELIOS-B: Vutrisiran reduces all-cause mortality
HELIOS-B試驗：Vutrisiran可降低轉甲狀腺素蛋白澱粉樣變心肌病（ATTR-CM）患者的全因死亡率
講者: Marianna Fontana
CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease
遺傳型和野生型ATTR-CM進行Nexiguran Ziclumeran（一種基於CRISPR/Cas9基因編輯療法的創新藥物）治療的療效對比
講者：Marianna Fontana
Late-breaking science: diagnostic methods and assessment
最新科學研究：診斷方法和評估策略
當地時間：5月17日13:45~14:45
Heart failure screening using the "EPOF" symptom questionnaire and fingerstick NT-proBNP test
使用“EPOF”症狀問卷和指尖血NT-proBNP測試進行心衰篩查
講者：Emmanuelle Berthelot
The HFpEF-ABA, H2FPEF, and HFA-PEFF scores and outcomes in individuals with HFpEF: a participant-level pooled analysis of 5 large-scale randomized clinical trials
5項大規模隨機臨床試驗的個體水平彙總分析：HFpEF患者使用HFpEF-ABA 評分、H2FPEF評分、或HFA-PEFF評分進行評估與結局差異
講者：John Ostrominski
Predictors of diagnostic discrepancy in heart failure with preserved ejection fraction between supine and upright exercise right heart catheterization
HFpEF患者進行仰臥位與直立位運動右心導管檢查診斷差異的預測因素
講者：Sergio Caravita
Pulmonary capillary wedge pressure measures at rest and during exercise: a comparison of supine and upright positions
靜息狀態及運動時的肺毛細血管楔壓測量：仰臥位 vs直立位
講者：Veraprapas kittipibul
Implementing an AI-ECG based algorithm to screen for left ventricular dysfunction in Kenya: a prospective cohort study
一項前瞻性佇列試驗：在肯亞應用基於演算法的AI-ECG篩查左心室功能障礙
講者：Ambarish Pandey
Liver stiffness as a non-invasive tool to assess central venous pressure: a pilot validation study in patients with heart failure or low ejection fraction
在HFrEF患者中進行的初步驗證試驗：肝臟硬度值可作為評估中心靜脈壓的非侵入性工具
講者: Nicolas Girerd
Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease
最新科學研究：心力衰竭、心肌病、肺動脈高壓和心臟瓣膜病
當地時間：5月17日16:00~17:00
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study
VELOCITY試驗：5 mg起始劑量維立西呱在心衰患者中應用的安全性和耐受性
講者： Stephen Greene
Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy
心肺運動試驗作為ATTR-CM臨床試驗中的新型事件終點
講者：Aldostefano Porcari
Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms
症狀輕微的梗阻性肥厚型心肌病患者使用Aficamten的有效性和安全性
講者：Iacopo Olivotto
Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2
在合併心衰的2型肺動脈高壓患者中，應用梯度去神經支配系統進行經皮肺動脈去神經術（PADN）
講者：Julio Nunez Villota
Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients
長效Fc-鬆弛素融合蛋白TX45對2型肺動脈高壓患者的血流動力學影響
講者：Anthony Muslin
Impact of dapagliflozin in quality of life of patients with aortic stenosis undergoing transcatheter aortic valve implantation
達格列淨對接受經導管主動脈瓣植入術（TAVI）的主動脈瓣狹窄患者生活治療的影響
講者：Clara Bonanad Lozano
Late-breaking science: screening for heart failure and prognostic models
最新科學研究：心力衰竭的篩查及預後模型
當地時間：5月18日08:30~09:30
Predicting heart failure events in patients with persistent left ventricular dysfunction following acute myocardial infarction: Insights from the WICD-MI study
來自WICD-MI試驗的見解：預測急性心梗後持續性左心室功能障礙患者的心衰事件風險
講者：Mathieu Echivard
Decentralized community-based rapid cardiac ultrasound triage for early heart failure detection using a hub-and-spoke model: findings from Heart2Miss initiative
Heart2Miss倡議的試驗結果：採用Hub-and-Spoke（中心輻射模式）的基於社群的分散式快速心臟超聲分診在早期心衰檢測中的療效
講者：Diana Foo
Validation of a novel, non-invasive system for remote monitoring of left ventricular filling pressure in heart failure patients
在心衰患者中驗證一種用於左心室充盈壓遠端監測的新型無創系統的療效
講者：Allan Bohm
Positive predictive value of a dynamic multiparameter heart failure risk score to identify worsening heart failure: primary results from the personalized therapy study
個性化治療研究的主要結果：利用動態多引數心衰風險評分識別心衰惡化的陽性預測值
講者：Charles Love
Impact of rurality and travel distance on the effectiveness of remote patient management in patients with heart failure: a pre-specified analysis of the randomised controlled TIM-HF2 trial
TIM-HF2隨機對照試驗預先指定的分析：鄉村和旅行距離對心衰患者遠端管理有效性的影響
講者：Stefan Stoerk
Prognostic value of heart failure stratification and cardiologist follow-up in a nationwide cohort of 600,000+ patients
超60萬例患者的全國性佇列試驗：心衰分層和心臟專科醫生隨訪的預後價值
講者：Guillaume Baudry
Hottest trials and trial updates (2)
最熱門試驗和試驗更新（2）
當地時間：5月18日10:45~12:15
DIGITHF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction
DIGIT-HF試驗：與近期HFrEF試驗相比的基線特徵
講者：Udo Bavendiek
CIRRUSHCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy
CIRRUS-HCM 2期多劑量試驗：新型心肌肌節調節劑EDG-7500在肥厚型心肌病中的安全性、耐受性，以及對血流動力學和功能能力的影響
講者：Anjali Owens
SEQUOIAHCM: Effect of aficamten treatment on patients with hypertrophic obstructive cardiomyopathy by geographical region
SEQUOIA-HCM試驗：在不同區域，aficamten治療對梗阻性肥厚型心肌病患者的影響
講者：Caroline Coats
GLADIATOR: The effects of geranylgeranylacetone in patients with HFpEF
GLADIATOR試驗：替普瑞酮對HFpEF患者的影響講者：Gerhard Hendrik Dirk Voordes
EASY-STOP: Home urinary sodium monitoring for personalized diuretic titration in heart failure
EASY-STOP試驗：針對心衰患者個體化利尿劑滴定的居家尿鈉監測
講者：Evelyne Meekers
HELPAHF: optimal target of PEEP in mechanically ventilated patients with AHF
HELP-AHF試驗：急性心衰（AHF）患者進行機械通氣的呼氣終末正壓（PEEP）的最佳目標
講者：Min-Seok Kim
PREFERHF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia
PREFER-HF試驗：與安慰劑相比，靜脈補鐵或口服補鐵治療對合並缺鐵性貧血的HFpEF患者的影響講者：Jose Luis Morales Rull
Late-breaking clinical trials in chronic heart failure
最新科學研究：慢性心衰
當地時間：5月18日13:45~14:45
Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial
REDICAE試驗：HFrEF患者停用利尿劑的安全性和耐受性
講者：Jesus Alberto Torres Zamudio
Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure
口服麥芽酚鐵補充劑可改善慢性心衰患者的缺鐵性貧血
講者：Tibor Kempf
Gene therapy for heart failure with preserved ejection fraction
HFpEF患者進行基因療法治療
講者：Marat Fudim
NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
NAN-CS101試驗：AB-1002基因療法治療NYHA III期心衰患者的首次人體1期開放標籤劑量遞增研究
講者：Roger J Hajjar
Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)
FIVE-STAR隨機、安慰劑對照機制研究：非奈利酮對2型糖尿病合併慢性腎臟病患者動脈僵硬度及心腎生物標誌物的影響
講者：Atsushi Tanaka
Cardio-microcurrent device for chronic heart failure: results from the C-MIC II randomized controlled trial
C-MIC II期隨機對照試驗：心臟微電流裝置在進行慢性心衰治療中的療效和安全性
講者：Stefan Anker
Registries and clinical trials: new onset and chronic heart failure
註冊和臨床試驗：新發和慢性心力衰竭
當地時間：5月18日16:00~17:00
Primary results of TITRATE-HF: 1-year continuous GRMT implementation, prognosis, and LVEF improvement in de novo heart failure with reduced ejection fraction
TITRATE-HF試驗的主要結果：在新診斷的HFrEF患者中，實施1年的持續GRMT對患者預後和LVEF改善的影響
講者：Jasper Brugts
Sudden cardiac arrest in patients with newly diagnosed NICM or MI/CAD – nationwide analysis of >19.000 patients with a WCD
對＞1.9萬佩戴穿戴式心臟除顫儀（WCD）患者的全國性分析：新診斷為非缺血性心肌病（NICM）或心梗/冠心病患者的心臟驟停情況
講者：Johann Bauersachs
Digoxin lowers pulmonary artery pressures and heart rate in patients with heart failure and reduced ejection fraction
地高辛可降低HFrEF患者的肺動脈壓力和心率
講者：Joann Lindenfeld
Increased perirenal adipose tissue thickness is associated with autonomic dysfunction and reduced CGRP in patients with HFpEF: a prospective observational study
一項前瞻性觀察性試驗：腎周脂肪厚度增加與HFpEF患者的自主神經功能障礙及降鈣素基因相關肽（CGRP）減少相關
講者：Onur Can Polat
Impact of M-TEER on health status in patients with moderate-to-severe functional mitral regurgitation and heart failure: results from RESHAPE-HF2
RESHAPE-HF2試驗結果：經導管二尖瓣緣對緣修復術（M-TEER）對中重度功能性二尖瓣反流合併心衰患者健康狀況的影響
講者：Javed Butler
Survival outcomes in younger patients with advanced heart failure: a comparative analysis of HeartMate 3 LVAD and heart transplant using MOMENTUM 3 and UNOS registry data
應用MOMENTUM 3和UNOS註冊資料，對比HeartMate 3 LVAD和心臟移植對年輕晚期心衰患者生存結局的影響
講者：Nir Uriel
Late-breaking science in acute heart failure
最新科學試驗：急性心力衰竭
當地時間：5月19日08:30~09:30
Kidney function trajectories before and after heart failure hospitalization in heart failure with reduced ejection fraction: findings from clinical trials and real-world data
來自臨床試驗和真實世界資料的試驗結果：HFrEF患者在因心衰住院前後的腎功能變化軌跡
講者：Nicolas Girerd
Sodium chloride vs. glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure
氯化鈉 vs 葡萄糖，作為容量替代療法在急性心衰減充血治療中的療效對比
講者：Jan Biegus
Combination oral acetazolamide and intravenous furosemide on acute decompensated heart failure
口服乙醯唑胺聯合靜脈注射呋塞米在急性失代償性心衰（ADHF）患者中的療效
講者：Inne Pratiwi Farissa
Impact of a urinary-sodium driven algorithm to optimize natriuresis in patients with ADHF: the FASTR trial
FASTR試驗：基於尿鈉的演算法對最佳化ADHF患者尿鈉排洩的影響
講者：Kevin Damman
A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock
探究心源性休克前期患者進行伊司他肟治療安全性和有效性的多中心、隨機、雙盲、安慰劑對照、平行試驗
講者：Jan Biegus
The effect of a switch in fluid management on health status in heart failure patients: a prespecified subanalysis of the FRESH-UP study
FRESH-UP試驗的預設亞組分析：液體管理方式改變對心衰患者健康狀況的影響
講者：Job Herrmann
Clinical trials updates in medical therapy
藥物治療的臨床研究更新
當地時間：5月19日13:45~14:45
Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial
FINEARTS-HF試驗的預設次要分析：非奈利酮在改善心衰再住院方面的療效
講者：Ankeet Bhatt
Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial
FINEARTS-HF試驗中，對於腎功能不同的射血分數輕度降低或保留的心衰患者，使用非奈利酮的風險和獲益權衡
講者：Safia Chatur
Intravenous ferric carboxymaltose in heart failure with iron deficiency
靜脈注射羧基麥芽糖鐵治療合併缺鐵的心衰患者
講者：Mahir Karakas
Efficacy of intravenous iron for the treatment of heart failure varies by method of meta-analysis: a Bayesian and frequentist reappraisal of the evidence
基於貝葉斯和頻率論方法對相關證據的重新評估：靜脈注射鐵劑治療心衰的療效因薈萃分析方法的不同而有所差異
講者：Alasdair Henderson
The effect of omecamtiv mecarbil on outcomes analysed using the win ratio: an exploratory analysis of GALACTIC-HF
GALACTIC-HF試驗的探索性分析：使用勝率評估omecamtiv mecarbil對治療結局的影響
講者：Kieran Docherty
EMPEROR-Preserved: association of echocardiographic features of diastolic dysfunction with the clinical efficacy of empagliflozin in HFpEF
EMPEROR-Preserved試驗：在HFpEF患者中，舒張功能障礙的超聲心動圖特徵與恩格列淨臨床療效的相關性
講者：Andrew Stewart Coats
Latest registries and observational studies
最新註冊和觀察性試驗
當地時間：5月20日08:30~09:30
Treatment uptake in the era of quadruple pharmacotherapy for heart failure with reduced ejection fraction: from prescriptions to patient adherence and persistence
在HFrEF四聯藥物治療時代，從處方開具起患者的用藥依從性和持續性
講者：Felix Lindberg
Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study
一項全國性註冊試驗：根據2021 ESC HF指南，HFrEF患者的藥物治療和預後改善情況
講者：Kristian Berge
Contemporary patient characterization and implementation of medical therapy for heart failure across the ejection fraction spectrum: the OPTIPHARM-HF registry
OPTIPHARM-HF註冊試驗：全射血分數譜心衰患者的當代特徵描述及藥物治療實施情況
講者：Riccardo Maria Inciardi
Timing of cardiac resynchronization therapy after optimal medical therapy in patients with heart failure: temporal trends, predictors and association with outcomes
行最佳藥物治療的心衰患者進行心臟再同步化治療的時機：時間趨勢、預測因素及與治療結局的相關性
講者：Alessandro Villaschi
Cardiac resynchronization therapy in heart failure: a target trial emulation study
一專案標模擬試驗：心衰患者進行心臟再同步化治療的療效
講者：Christian Basile
The MagMa study – detection of myocarditis through quantum technology
MagMa試驗：透過量子技術檢測心肌炎
講者：Bettina Heidecker
信源：ESC-HFA 官網